465 related articles for article (PubMed ID: 17982704)
1. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Hughes A; Rogers MJ; Idris AI; Crockett JC
Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
[TBL] [Abstract][Full Text] [Related]
2. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of D-003, a mixture of high-molecular-weight aliphatic acids from sugarcane wax, and pravastatin on bones and osteoclast apoptosis of ovariectomized rats.
Mendoza S; Noa M; Mas R; Mendoza N
Drugs Exp Clin Res; 2005; 31(5-6):181-91. PubMed ID: 16425974
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
5. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
6. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
7. Pleiotropic effects of statins in atherosclerosis and diabetes.
Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
[TBL] [Abstract][Full Text] [Related]
8. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
9. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
Woo JT; Kasai S; Stern PH; Nagai K
J Bone Miner Res; 2000 Apr; 15(4):650-62. PubMed ID: 10780857
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease.
Wu B; Elmariah S; Kaplan FS; Cheng G; Mohler ER
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):592-7. PubMed ID: 15618546
[TBL] [Abstract][Full Text] [Related]
11. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation.
Oxlund H; Andreassen TT
Bone; 2004 Apr; 34(4):609-18. PubMed ID: 15050891
[TBL] [Abstract][Full Text] [Related]
13. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo.
Idris AI; Landao-Bassonga E; Ralston SH
Bone; 2010 Apr; 46(4):1089-99. PubMed ID: 20096813
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
Moran EL; Fornasier TL; Bogoch TR
J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
[TBL] [Abstract][Full Text] [Related]
15. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
16. [Statins and osteoporosis].
Svejda P
Vnitr Lek; 2006 Dec; 52(12):1190-3. PubMed ID: 17299913
[TBL] [Abstract][Full Text] [Related]
17. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
18. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
Luan Z; Chase AJ; Newby AC
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370
[TBL] [Abstract][Full Text] [Related]
19. Statins and osteoporosis: new role for old drugs.
Jadhav SB; Jain GK
J Pharm Pharmacol; 2006 Jan; 58(1):3-18. PubMed ID: 16393459
[TBL] [Abstract][Full Text] [Related]
20. Statins, fracture risk, and bone remodeling.
Luisetto G; Camozzi V
J Endocrinol Invest; 2009; 32(4 Suppl):32-7. PubMed ID: 19724164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
